MedTrace Logo

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

NCT07241416 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2026-05-11

No results posted yet for this study

Summary

This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.

Conditions

  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Interventions

DRUG

Rezvilutamide Tablets

Rezvilutamide tablets, oral administration.

DRUG

Enzalutamide Soft Capsules

Enzalutamide soft capsules, oral administration.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-05
Primary Completion
2027-03-31
Completion
2028-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07241416 on ClinicalTrials.gov